Study Raises Questions About 'Wait & Watch' for Medium-Size Polyps

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 12
Volume 15
Issue 12

A study published in the December issue of Gastroenterology has shown that medium-sized polyps found in the colon with flexible sigmoidoscopy and subsequently evaluated by full colonoscopy are associated with a significant number of advanced adenomas and cancers.

PITTSBURGH—A study published in the December issue of Gastroenterology has shown that medium-sized polyps found in the colon with flexible sigmoidoscopy and subsequently evaluated by full colonoscopy are associated with a significant number of advanced adenomas and cancers.

These findings raise questions about taking a "wait and watch" approach to medium-sized polyps and delaying referral to colonoscopy, said Robert E. Schoen, MD, MPH, lead author of the study and professor of medicine and epidemiology, University of Pittsburgh School of Medicine. He noted that wait and watch could become more popular with wider use of newer screening tests that visualize polyps but do not remove them, such as CT (virtual) colonoscopy and less-invasive colonoscopies on the horizon such as the Aer-O-Scope (a miniaturized, self-propelling, self-navigating, disposable colonoscopic camera).

There is general agreement that colonoscopy is needed when a polyp 1.0 cm in size or larger is found, he said, but there is much greater uncertainty about the role of colonoscopy when the polyps are less than 1.0 cm."Because of issues of expense and risk, determining a specific threshold for subsequent procedures after these observational screening tests becomes an important issue," he said.

The study included 10,850 men and women enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial, a randomized, community-based study evaluating the effectiveness of cancer screening tests on site-specific mortality at 10 US centers. The participants had an abnormal flexible sigmoidoscopy with at least one detectable polyp and subsequently underwent a diagnostic colonoscopy within 1 year.

Polyps 0.5 to 0.9 cm were found in 2,183 men and 1,426 women through flexible sigmoidoscopy. When the men and women underwent diagnostic colonoscopy, 14.5% of the women and 15.9% of the men were diagnosed with advanced adenomas, and 0.6% of the women and 0.7% of the men were diagnosed with cancer. In some cases, the medium-sized polyps were considered large after removal, he said, and some small polyps were found to have important, adverse pathologic characteristics.

"The implication is that where we draw the line when assessing polyp size and referral to colonoscopy has to be carefully considered," Dr. Schoen said. "These results offer a cautionary note to waiting and watching."

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content